 |
|
Autologous Transplantation of Adrenal Medulla in Parkinson's Disease18-Month Results
C. W. Olanow, MD, FRCPC;
W. Koller, MD, PhD;
C. G. Goetz, MD;
G. T. Stebbins, PhD;
D. W. Cahill, MD;
L. L. Gauger;
R. Morantz, MD;
R. D. Penn, MD;
C. M. Tanner, MD;
H. L. Klawans, MD;
K. M. Shannon, MD;
C. L. Comella, MD;
T. Witt, MD
Arch Neurol. 1990;47(12):1286-1289.
Abstract
• Eighteen of 19 patients who underwent autologous adrenal medullary transplantation to the right caudate nucleus have been followed up for 18 months. During the course of this study, a statistically significant improvement was noted in percent "on" time, percent "on" time without dyskinesia, activity of daily living (ADL) scores during the "on" stages, and ADL, motor, and Schwab-England scores during the "off" stages. Benefits tended to be maximal at 6 months and to gradually lessen thereafter, although statistically significant improvement in comparison with baseline was still present at 18 months for ADL, motor, and Hoehn-Yahr scores during the "off" stages. Almost all parameters had deteriorated by 18 months compared with 12 months, including those remaining significantly improved in comparison with baseline. These patterns were similar for each of the three participating centers. Complications were largely restricted to the perioperative period.
Author Affiliations
From the Departments of Neurology, University of South Florida, Tampa (Drs Olanow and Cahill and Ms Gauger), University of Kansas, Kansas City (Drs Koller and Morantz), and Rush-Presbyterian St Luke's Medical Center, Chicago, Ill (Drs Goetz, Stebbins, Penn, Tanner, Klawans, Shannon, Comella, and Witt).
Footnotes
Accepted for publication August 1, 1990.
Reprint requests to Department of Neurology, University of South Florida, 4 Columbia Dr, Suite 410, Tampa, FL 33606 (Dr Olanow).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease
Farag et al.
Neurology 2009;73:1095-1102.
ABSTRACT
| FULL TEXT
Present and future directions in the management of motor complications in patients with advanced PD
Olanow
Neurology 2003;61:S24-33.
FULL TEXT
Progenitor Cell Biology: Implications for Neural Regeneration
Mehler and Kessler
Arch Neurol 1999;56:780-784.
ABSTRACT
| FULL TEXT
Switching dopamine agonists in advanced Parkinson's disease: Is rapid titration preferable to slow?
Goetz et al.
Neurology 1999;52:1227-1227.
ABSTRACT
| FULL TEXT
Understanding Parkinson Disease
Cummings
JAMA 1999;281:376-378.
FULL TEXT
A 61-Year-Old Man With Parkinson's Disease-Reply
Olanow
JAMA 1996;276:104-104.
ABSTRACT
|
